BRD4 and acute myeloid leukemia: GNE-987 (Fig. 2), containing a potent tetracyclic BRD4 inhibitor, exhibited extremely high activities in degradation of BRD4 and growth inhibition of acute myeloid leukemia EOL-1 cells in low pM levels [44].